Patients included in this study
| Characteristic . | No/inactive cGVHD (n = 62) . | Active cGVHD (n = 47) . | P value . |
|---|---|---|---|
| Median age (range), y | 53 (20-72) | 49 (22-70) | .28 |
| Sex, females, n (%) | 29 (47) | 20 (43) | .70 |
| Median time after transplant (range), mo | 29 (7-137) | 29 (11-195) | .74 |
| Conditioning regimen (%) | .85 | ||
| Myeloablative | 35 (56) | 25 (53) | |
| Nonmyeloablative | 27 (44) | 22 (47) | |
| Source of graft (%) | .81 | ||
| Peripheral blood | 50 (81) | 37 (79) | |
| BM | 12 (19) | 10 (21) | |
| HLA matching (%) | .49 | ||
| Matched, unrelated | 33 (52) | 27 (57) | |
| Matched, related | 29 (47) | 19 (40) | |
| Mismatched | 0 (0) | 1 (2) | |
| Immunosuppressive treatment (%) | |||
| Prednisone, <0.5 mg/kg | 62 (100) | 44 (94) | .08 |
| MMF | 3 (1.5) | 8 (17) | .05 |
| Calcineurin inhibitor | 7 (11) | 18 (38) | .0000 |
| Rapamycin | 7 (11) | 7 (15) | .58 |
| Initial disease (%) | .05 | ||
| AML/ALL from MDS | 1 (2) | 4 (9) | |
| ALL | 5 (8) | 4 (9) | |
| AML | 12 (19) | 10 (21) | |
| CML | 12 (19) | 3 (6) | |
| CLL | 1 (2) | 6 (13) | |
| MDS | 9 (15) | 6 (13) | |
| NHL | 10 (16) | 6 (13) | |
| MM | 2 (3) | 0 (0) | |
| AA | 4 (6) | 0 (0) | |
| Other | 6 (10) | 8 (17) |
| Characteristic . | No/inactive cGVHD (n = 62) . | Active cGVHD (n = 47) . | P value . |
|---|---|---|---|
| Median age (range), y | 53 (20-72) | 49 (22-70) | .28 |
| Sex, females, n (%) | 29 (47) | 20 (43) | .70 |
| Median time after transplant (range), mo | 29 (7-137) | 29 (11-195) | .74 |
| Conditioning regimen (%) | .85 | ||
| Myeloablative | 35 (56) | 25 (53) | |
| Nonmyeloablative | 27 (44) | 22 (47) | |
| Source of graft (%) | .81 | ||
| Peripheral blood | 50 (81) | 37 (79) | |
| BM | 12 (19) | 10 (21) | |
| HLA matching (%) | .49 | ||
| Matched, unrelated | 33 (52) | 27 (57) | |
| Matched, related | 29 (47) | 19 (40) | |
| Mismatched | 0 (0) | 1 (2) | |
| Immunosuppressive treatment (%) | |||
| Prednisone, <0.5 mg/kg | 62 (100) | 44 (94) | .08 |
| MMF | 3 (1.5) | 8 (17) | .05 |
| Calcineurin inhibitor | 7 (11) | 18 (38) | .0000 |
| Rapamycin | 7 (11) | 7 (15) | .58 |
| Initial disease (%) | .05 | ||
| AML/ALL from MDS | 1 (2) | 4 (9) | |
| ALL | 5 (8) | 4 (9) | |
| AML | 12 (19) | 10 (21) | |
| CML | 12 (19) | 3 (6) | |
| CLL | 1 (2) | 6 (13) | |
| MDS | 9 (15) | 6 (13) | |
| NHL | 10 (16) | 6 (13) | |
| MM | 2 (3) | 0 (0) | |
| AA | 4 (6) | 0 (0) | |
| Other | 6 (10) | 8 (17) |
All patients provided consent, all samples were obtained, and all studies were approved under the institutional review board protocols of Duke University, the National Institutes of Health, and the Dana-Farber Cancer Institute. Statistical comparisons between groups (active cGVHD vs no/inactive cGVHD) were performed using the Fisher exact test.
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma.